Outpatient treatment initiators and individuals with moderately severe or severe pretreatment depression were most likely to benefit from ketamine treatment over electroconvulsive therapy (ECT) for treatment-resistant depression (TRD), a newly published analysis has found. Individuals with the most severe pretreatment depression saw greater benefit from ECT early in treatment. Study results were published online June 25, 2024, in JAMA Network Open.
Research data suggest an association between antipsychotic-induced hyperprolactinemia and higher risk of breast cancer (Rahman et al., 2022; also, see “Breast cancer risk with antipsychotic use linked to prolactin levels;” https://doi.org/10.1002/pu.30853). This is likely secondary to the anti-dopaminergic properties of antipsychotics, especially those of first-generation agents.
Citalopram (generic) — Celexa (brand)
Two Phase 3 trials have found that tirzepatide, a medication used to treat type 2 diabetes, reduced apnea events and body weight in patients with obstructive sleep apnea and obesity. Tirzepatide had comparable safety results to placebo in the two trials.
A systematic review and meta-analysis encompassing 79 studies has found that around one-third of patients who discontinue antidepressant medication will experience adverse symptoms, but only around 1 in 30 will experience severe discontinuation symptoms. An analysis of individual antidepressants found that imipramine, desvenlafaxine, and venlafaxine were associated with the highest incidence of discontinuation symptoms. Results were published online June 5, 2024, in Lancet Psychiatry.
A 12-week randomized trial involving 147 participants has found that topiramate was as effective as naltrexone in reducing drinking behaviors in patients with alcohol use disorder (AUD). A secondary analysis found no association between two gene polymorphisms and patient response to the medication treatments.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：